## Founding Date | 2010 |

## Total Funding | $161 m |

## Investors | Kleiner Perkins, New Enterprise Associates, T. Rowe Price, InterWest Partners, Pappas Ventures, Deerfield, Leerink Partners |

In total, TESARO had raised $161 m. TESARO is a subsidiary of GSK

USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|---|

## Revenue | 44.8m | 223.3m | ||||

| 14040% | |||||

## Cost of goods sold | 268.0k | 1.3m | 41.1m | |||

## Gross profit | (268.0k) | 43.6m | 182.2m | |||

| 97% | 82% | ||||

## R&D expense | 47.2m | 75.7m | 118.4m | 155.4m | 235.1m | 308.7m |

## General and administrative expense | 6.7m | 14.8m | 23.9m | 78.7m | 158.6m | 336.8m |

## Operating expense total | 53.9m | 90.5m | 142.4m | 235.8m | 414.5m | 661.7m |

## EBIT | (61.9m) | (92.4m) | (167.3m) | (236.0m) | (370.9m) | (479.5m) |

| (828%) | (215%) | ||||

## Interest expense | 3.8m | |||||

## Interest income | 152.0k | 83.0k | 24.0k | 48.0k | 1.4m | 4.1m |

## Pre tax profit | (171.0m) | (251.4m) | (386.0m) | (494.8m) | ||

## Income tax expense | 1.5m | 1.3m | ||||

## Net Income | (61.8m) | (92.4m) | (171.0m) | (251.4m) | (387.5m) | (496.1m) |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|---|

## Cash | 125.4m | 130.3m | 256.9m | 230.1m | 785.9m | 643.1m |

## Accounts Receivable | 679.0k | 5.3m | 53.4m | |||

## Prepaid Expenses | 1.2m | 4.0m | 1.7m | 4.6m | 33.5m | |

## Inventories | 1.1m | 14.7m | 57.9m | |||

## Current Assets | 126.6m | 134.3m | 258.6m | 236.5m | 814.8m | 788.0m |

## PP&E | 219.0k | 440.0k | 1.0m | 2.8m | 6.6m | 9.7m |

## Total Assets | 127.4m | 135.6m | 263.9m | 255.3m | 839.8m | 862.2m |

## Accounts Payable | 3.2m | 1.9m | 6.1m | 8.0m | 5.2m | 4.2m |

## Current Liabilities | 11.7m | 12.4m | 24.4m | 46.7m | 76.8m | 166.2m |

## Long-term debt | 293.7m | |||||

## Total Debt | 293.7m | |||||

## Total Liabilities | 139.8m | 168.4m | 228.6m | 613.1m | ||

## Common Stock | 3.0k | 3.0k | 4.0k | 4.0k | 5.0k | |

## Additional Paid-in Capital | 202.8m | 302.6m | 474.6m | 688.8m | 1.6b | 1.7b |

## Retained Earnings | (87.1m) | (179.5m) | (350.5m) | (601.9m) | (990.7m) | (1.5b) |

## Total Equity | 115.7m | 123.2m | 124.1m | 86.9m | 611.2m | 249.1m |

## Debt to Equity Ratio | 1.2 x | |||||

## Debt to Assets Ratio | 0.3 x | |||||

## Financial Leverage | 1.1 x | 1.1 x | 2.1 x | 2.9 x | 1.4 x | 3.5 x |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|---|

## Net Income | (61.8m) | (92.4m) | (171.0m) | (251.4m) | (387.5m) | (496.1m) |

## Depreciation and Amortization | 64.0k | 179.0k | 349.0k | 9.5m | ||

## Accounts Receivable | (679.0k) | (4.7m) | (47.1m) | |||

## Inventories | (1.1m) | (13.6m) | (60.0m) | |||

## Accounts Payable | 2.6m | (1.3m) | 4.2m | 1.9m | (2.8m) | (1.0m) |

## Cash From Operating Activities | (42.8m) | (84.9m) | (117.5m) | (194.5m) | (287.7m) | (400.1m) |

## Purchases of PP&E | (165.0k) | (400.0k) | (1.0m) | (2.3m) | (2.9m) | (6.0m) |

## Cash From Investing Activities | (8.0m) | (2.3m) | (25.9m) | (19.8m) | (23.3m) | (66.5m) |

## Cash From Financing Activities | 136.3m | 92.1m | 269.9m | 187.6m | 866.9m | 323.3m |

## Net Change in Cash | 85.6m | 4.9m | 126.6m | (26.7m) | 555.7m | (142.8m) |

## Interest Paid | 6.1m | 6.0m | 6.0m | |||

## Income Taxes Paid | 573.0k |

- Source: SEC Filings

- Source: SEC Filings

USD | Q2, 2012 |
---|---|

## Financial Leverage | 7.8 x |